• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢适应性丧失导致 CAR-NK 细胞治疗后的肿瘤耐药,并可通过细胞因子工程克服。

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26.

DOI:10.1126/sciadv.add6997
PMID:37494448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10371011/
Abstract

Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with early-phase clinical studies showing encouraging responses. However, the transcriptional signatures that control the fate of CAR-NK cells after infusion and factors that influence tumor control remain poorly understood. We performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-NK cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse. Using a preclinical model of noncurative lymphoma and samples from a responder and a nonresponder patient treated with CAR19/IL-15 NK cells, we observed the emergence of NK cell clusters with distinct patterns of activation, function, and metabolic signature associated with different phases of in vivo evolution and tumor control. Interaction with the highly metabolically active tumor resulted in loss of metabolic fitness in NK cells that could be partly overcome by incorporation of IL-15 in the CAR construct.

摘要

嵌合抗原受体 (CAR) 修饰的自然杀伤 (NK) 细胞具有广阔的应用前景,早期临床研究显示出可喜的反应。然而,输注后控制 CAR-NK 细胞命运的转录特征以及影响肿瘤控制的因素仍知之甚少。我们通过单细胞 RNA 测序和质谱细胞术来研究过继转移后 CAR-NK 细胞的异质性及其体内演变,从肿瘤控制到复发的阶段。我们使用非治愈性淋巴瘤的临床前模型以及接受 CAR19/IL-15 NK 细胞治疗的应答者和无应答者患者的样本,观察到具有不同激活、功能和代谢特征的 NK 细胞簇的出现,这些特征与体内演变和肿瘤控制的不同阶段相关。与高度代谢活跃的肿瘤相互作用导致 NK 细胞代谢适应性丧失,而在 CAR 构建中加入 IL-15 可以在一定程度上克服这一问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/6d71c2435a15/sciadv.add6997-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/855551b2a6ec/sciadv.add6997-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/a1a1e56e194c/sciadv.add6997-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/461f30b40bec/sciadv.add6997-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/d780636afdf6/sciadv.add6997-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/859c24fc582f/sciadv.add6997-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/d77863da1236/sciadv.add6997-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/6d71c2435a15/sciadv.add6997-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/855551b2a6ec/sciadv.add6997-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/a1a1e56e194c/sciadv.add6997-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/461f30b40bec/sciadv.add6997-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/d780636afdf6/sciadv.add6997-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/859c24fc582f/sciadv.add6997-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/d77863da1236/sciadv.add6997-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a533/10371011/6d71c2435a15/sciadv.add6997-f7.jpg

相似文献

1
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.代谢适应性丧失导致 CAR-NK 细胞治疗后的肿瘤耐药,并可通过细胞因子工程克服。
Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26.
2
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.通过工程化 PGC-1α 进行代谢重编程可改善针对实体瘤的人嵌合抗原受体 T 细胞疗法。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006522.
3
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.通过联合原发性嵌合抗原受体自然杀伤细胞(CAR NK细胞)和放射疗法精准靶向横纹肌肉瘤。
J Immunother Cancer. 2025 Jul 7;13(7):e011330. doi: 10.1136/jitc-2024-011330.
4
Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity.携带CCL19、CCR2B、高亲和力CD16、IL-15和NKG2D复合物的人诱导多能干细胞衍生的自然杀伤细胞增强抗实体瘤活性。
Stem Cell Res Ther. 2025 Jul 15;16(1):373. doi: 10.1186/s13287-025-04461-9.
5
Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner.癌症治疗中新兴的联合CAR-NK细胞疗法:寻找舞伴。
Mol Ther. 2025 Jan 3. doi: 10.1016/j.ymthe.2024.12.057.
6
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
7
Co-expression of IL-15/IL-15Ra complex enhances NKG2D-CAR T cell-mediated anti-pancreatic cancer immunity by activating the JAK/STAT5 signaling pathway.IL-15/IL-15Ra复合物的共表达通过激活JAK/STAT5信号通路增强NKG2D嵌合抗原受体T细胞介导的抗胰腺癌免疫。
Front Immunol. 2025 Jun 23;16:1498706. doi: 10.3389/fimmu.2025.1498706. eCollection 2025.
8
SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy.脾酪氨酸激酶(SYK)负向调节免疫受体酪氨酸活化基序(ITAM)介导的人自然杀伤(NK)细胞信号传导及CD19嵌合抗原受体(CAR)NK细胞的功效。
J Immunol. 2025 Mar 9;214(3):384-98. doi: 10.1093/jimmun/vkaf012.
9
Turning "trashed" genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells.将“废弃”的基因组位点转化为用于在T细胞和自然杀伤细胞中整合嵌合抗原受体的宝贵位点。
Mol Ther. 2025 Apr 2;33(4):1368-1379. doi: 10.1016/j.ymthe.2025.02.028. Epub 2025 Feb 20.
10
CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.嵌合抗原受体自然杀伤细胞疗法(CAR-NK),一种治疗癌症的卓越策略,尤其适用于妇科肿瘤。
Immun Inflamm Dis. 2025 Jun;13(6):e70210. doi: 10.1002/iid3.70210.

引用本文的文献

1
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.全基因组CRISPR筛选确定增强CAR-NK细胞抗肿瘤效力的关键靶点。
Cancer Cell. 2025 Aug 18. doi: 10.1016/j.ccell.2025.07.021.
2
Unraveling NK cell heterogeneity through single-cell sequencing: insights from physiological and tumor contexts for clinical applications.通过单细胞测序揭示自然杀伤细胞的异质性:来自生理和肿瘤背景的见解及其临床应用
Front Immunol. 2025 Jul 21;16:1612352. doi: 10.3389/fimmu.2025.1612352. eCollection 2025.
3
Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells.

本文引用的文献

1
Expression of Immune Related Genes and Possible Regulatory Mechanisms in Alzheimer's Disease.阿尔茨海默病中免疫相关基因的表达及可能的调控机制。
Front Immunol. 2021 Nov 5;12:768966. doi: 10.3389/fimmu.2021.768966. eCollection 2021.
2
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.clusterProfiler 4.0:用于解释组学数据的通用富集工具。
Innovation (Camb). 2021 Jul 1;2(3):100141. doi: 10.1016/j.xinn.2021.100141. eCollection 2021 Aug 28.
3
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.
将条形码化抗CD20嵌合抗原受体慢病毒递送至恒河猴和人类自然杀伤细胞的优化
Mol Ther Methods Clin Dev. 2025 Apr 18;33(2):101473. doi: 10.1016/j.omtm.2025.101473. eCollection 2025 Jun 12.
4
CyTOF as a suitable tool for stratification and monitoring of cancer patients.质谱流式细胞术作为一种适用于癌症患者分层和监测的工具。
J Transl Med. 2025 Jul 1;23(1):724. doi: 10.1186/s12967-025-06764-0.
5
Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma.溶瘤腺免疫疗法可改善同种异体过继性HER2嵌合抗原受体自然杀伤细胞(HER2.CAR-NK)针对胰腺导管腺癌的功能。
Mol Ther Oncol. 2025 May 26;33(2):201006. doi: 10.1016/j.omton.2025.201006. eCollection 2025 Jun 18.
6
CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.嵌合抗原受体自然杀伤细胞(CAR-NK细胞):利用自然杀伤细胞的力量进行晚期癌症治疗。
Front Immunol. 2025 May 30;16:1603757. doi: 10.3389/fimmu.2025.1603757. eCollection 2025.
7
Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature.IL-15与CCL21的共表达增强了嵌合抗原受体自然杀伤细胞(CAR-NK细胞)与T细胞协同消除肿瘤的能力,并赋予它们PI3K/AKT/mTOR信号特征。
J Immunother Cancer. 2025 Jun 15;13(6):e010822. doi: 10.1136/jitc-2024-010822.
8
CD28 signaling domain boosts persistence and anti-tumor activity of stem cell-derived CD19-CAR-NK cells.CD28信号结构域增强了干细胞来源的CD19嵌合抗原受体自然杀伤细胞(CD19-CAR-NK细胞)的持久性和抗肿瘤活性。
iScience. 2025 Apr 29;28(6):112548. doi: 10.1016/j.isci.2025.112548. eCollection 2025 Jun 20.
9
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells.CREM是自然杀伤细胞中CAR和IL-15信号传导的一个调节检查点。
Nature. 2025 Jun 4. doi: 10.1038/s41586-025-09087-8.
10
Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies.嵌合抗原受体自然杀伤细胞在血液系统恶性肿瘤治疗中的新兴作用。
Cancers (Basel). 2025 Apr 26;17(9):1454. doi: 10.3390/cancers17091454.
符合 GMP 标准的通用抗原呈递细胞(uAPC)可增强武装脐血 CAR-NK 细胞的代谢适应性和抗肿瘤活性。
Front Immunol. 2021 Feb 26;12:626098. doi: 10.3389/fimmu.2021.626098. eCollection 2021.
4
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
5
FDA approves fourth CAR-T cell therapy.美国食品药品监督管理局批准第四种嵌合抗原受体T细胞疗法。
Nat Rev Drug Discov. 2021 Mar;20(3):166. doi: 10.1038/d41573-021-00031-9.
6
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.新型 CAR 疗法的前景,重点关注 CAR-NK 细胞:在对抗癌症的竞赛中,CAR 工程化 T 细胞之外的未来。
Cancer Discov. 2021 Jan;11(1):45-58. doi: 10.1158/2159-8290.CD-20-0556. Epub 2020 Dec 4.
7
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.靶向细胞因子检查点增强了装甲脐血 CAR-NK 细胞的适应性。
Blood. 2021 Feb 4;137(5):624-636. doi: 10.1182/blood.2020007748.
8
Overcoming hypoxia-induced functional suppression of NK cells.克服缺氧诱导的 NK 细胞功能抑制。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2019-000246.
9
Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer.乳腺癌中肿瘤糖酵解与免疫/炎症功能之间关联的综合分析。
J Transl Med. 2020 Feb 18;18(1):92. doi: 10.1186/s12967-020-02267-2.
10
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.